Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study.

ABSTRACT: Current pharmacological agents for depression have limited efficacy in achieving remission. Developing and validating new medications is challenging due to limited biological targets. This study aimed to link electrophysiological data and symptom improvement to better understand mechanisms underlying treatment response. Longitudinal changes in neural oscillations were assessed using resting-state electroencephalography (EEG) data from two Canadian Biomarker Integration Network in Depression studies, involving pharmacological and cognitive behavioral therapy (CBT) trials. Patients in the pharmacological trial received eight weeks of escitalopram, with treatment response defined as ≥ 50% decrease in Montgomery-Åsberg Depression Rating Scale (MADRS). Early (baseline to week 2) and late (basel

SUBMITTER: Schwartzmann B 

PROVIDER: S-EPMC11470922 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature